Skip to content

Fluvoxamine

A Repeat Of Ivermectin? It’s Time to Approve Fluvoxamine for Early COVID Treatment

All 3 were placebo-controlled randomized controlled trials that recruited unvaccinated, symptomatic adults with microbiologically confirmed SARS-CoV-2 infection who were within 6 to 7 days of infection and not requiring oxygen.  … Overall, the median age of participants was between 46 and 50, 55% to 72% of participants were female, 44% to 56% were obese.  … No trials included vaccinated patients and all trials predated both the Delta and Omicron variants.